文献速递前列腺癌

聚焦不可逆电穿孔作为局限性前列腺癌首选治疗后的肿瘤学与生活质量结局:一项活检监测的前瞻性队列研究

Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
PubMed 文献 · Eur Urol Oncol · 2019-05-16

该前瞻性队列纳入2013年2月至2018年8月接受初次聚焦不可逆电穿孔(IRE)的123例局限性前列腺癌患者,中位随访36个月。3年无失败生存率为96.75%,转移免费生存率99%,总生存率100%;mpMRI对6个月时野内残留病灶的阴性预测值为94%、灵敏度40%。返回问卷者中98.8%保持无尿垫,76%勃起功能无变化。

要点

  • 初次聚焦IRE后3年无失败生存率96.75%,转移免费生存率99%,总生存率100%。
  • 治疗后12个月经会阴模板定位活检显示野内复发者占2.7–9.8%。
  • mpMRI检测6个月时野内残留病灶的阴性预测值94%、灵敏度40%。

核心结论

  • 在经选择的局限性临床显著前列腺癌患者中,聚焦IRE具有令人满意的短期肿瘤学结局且对患者生活质量影响极小。

研究设计与样本

  • 前瞻性数据库研究,纳入2013年2月至2018年8月接受初次聚焦IRE的患者,至少12个月随访者123例,中位随访36个月(IQR 24–52个月)。
  • 112例(91%)为美国国家综合癌症网络(NCCN)中危,11例(9%)为低危;ISUP分级1级12例(9.8%)、2级88例(71.5%)、3级23例(18.7%)。
  • 干预为前列腺癌病灶的聚焦IRE消融;随访包括系列PSA、多参数磁共振成像(mpMRI)及12个月经会阴模板定位活检(TTMB)。

主要发现

  • 中位年龄68岁(IQR 62–73岁),术前中位PSA 5.7 ng/ml(IQR 3.8–8.0 ng/ml)。
  • 治疗后TTMB显示野内复发者占2.7–9.8%;3年无失败生存率96.75%,转移免费生存率99%,总生存率100%。
  • 18例需挽救治疗,其中12例重复IRE、6例全腺体治疗。
  • mpMRI检测治疗后6个月野内残留病灶的阴性预测值94%、灵敏度40%。
  • 返回问卷者中80/81(98.8%)保持无尿垫,40/53(76%)勃起功能无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Focal irreversible electroporation (IRE) can be used to treat men with localised prostate cancer (PCa) with reduced impact on quality of life (QoL). OBJECTIVE: To assess oncological and functional outcomes. DESIGN, SETTING, AND PARTICIPANTS: To report on a prospective database of patients undergoing primary IRE between February 2013 and August 2018. A minimum of 12-mo follow-up was available for 123 patients. Median follow-up was 36 mo (interquartile range [IQR] 24-52 mo). A total of 112 (91%) patients had National Comprehensive Cancer Network intermediate risk and 11 (9%) had low risk. A total of 12 (9.8%) had International Society of Urological Pathology (ISUP) grade 1, 88 (71.5%) had ISUP 2, and 23 (18.7%) had ISUP 3. INTERVENTION: Focal IRE ablation of PCa lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Follow-up involved serial prostate-specific antigen (PSA), multiparametric magnetic resonance imaging (mpMRI), and transperineal template mapping biopsy (TTMB) at 12 mo. Failure-free survival (FFS) was defined as progression to whole-gland or systemic treatment or metastasis/death. Functional outcomes were assessed. RESULTS AND LIMITATIONS: Median age was 68yr (IQR 62-73yr). Median preoperative PSA was 5.7ng/ml (IQR 3.8-8.0ng/ml). On post-treatment TTMB, in-field recurrence was present in 2.7-9.8% of patients. FFS at 3yr was 96.75%, metastasis-free survival 99%, and overall survival 100%. A total of 18 patients required salvage treatment (12 had repeat IRE; six had whole-gland treatment). The negative predictive value of mpMRI was 94% and sensitivity 40% for detecting in-field residual disease 6 mo after treatment. Among patients who returned questionnaires, 80/81 (98.8%) remained pad free and 40/53 (76%) had no change in erectile function. CONCLUSIONS: Focal IRE in select patients with localised clinically significant PCa has satisfactory short-term oncological outcomes with a minimal impact on patient QoL. PATIENT SUMMARY: In this study, 123 patients underwent focal therapy using irreversible electroporation. Follow-up biopsy was clear of residual disease in 90.2-97.3% of patients. Of patients, 96.75% avoided whole gland treatment at 3yr.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Blazevski A, Scheltema MJ, Yuen B, et al. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol Oncol. 2019. PMID: 31103721. doi:10.1016/j.euo.2019.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。